Kallyope
PrivateLast Round
Grant
May 10, 2023
Est. Valuation
$1.14B
Total Funding Raised
$487.2M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Kallyope is a biotechnology company that integrates advanced technologies to understand gut-brain biology for the development of novel therapeutics targeting neurological and metabolic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Kallyope Comparables
Compare Kallyope with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Structure Therapeutics | 79% | |
| Axial Therapeutics | 79% | |
| Roche Holding | 78% |
Kallyope Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | May 10, 2023 | ||||
| Series D | Feb 15, 2022 | ||||
| Series C | Mar 25, 2020 | ||||
| Series B | Dec 5, 2018 | ||||
| Series A | Dec 10, 2015 |
Key People
Founding team and executive leadership
Kallyope Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Column Group | Series B, Series C, Series A, Series D |
| Parkwood | Series D |
| StepStone Group | Series D, Series C |
| Lux Capital | Series D, Series B, Series C, Series A |
| The Chernin Group | Series A, Series B, Series C, Series D |
| Two Sigma Ventures | Series D, Series B, Series C |
| Bill & Melinda Gates Foundation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 23, 2026
Monthly visitors increased 51% MoM.
- Mar 5, 2026
Presented Phase 2b migraine study results at the AAN Annual Meeting.
Recent news
Latest coverage and updates
- sells_assets_toSep 21, 2026
Kallyope sold assets to Novo Nordisk A/S on Sep 18th '26.
- sells_assets_toSep 18, 2026
Kallyope sold assets to Novo Nordisk Inc. on Sep 18th '26.
Kallyope Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Kallyope's valuation, stock price, and market status.
Is Kallyope a public or private company?
Kallyope is a private company.
What is the current stock price of Kallyope?
Kallyope is a private company with no public stock price. No recent secondary market data is available.
How much is Kallyope worth (valuation)?
Kallyope's valuation is estimated at $1.1B based on funding round data.
Can I buy Kallyope stock?
Kallyope shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Kallyope's last funding round?
Kallyope's most recent funding round was Grant on February 15, 2022.
Who are the main investors in Kallyope?
Key investors in Kallyope include The Column Group, Lux Capital, The Chernin Group, Mubadala Investment Company.
Will Kallyope IPO soon?
No public IPO plans have been announced for Kallyope.
How can I track Kallyope secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Kallyope's secondary market activity and sign up for updates.